Stem cell transplantation for lymphoma
暂无分享,去创建一个
[1] Scott E. Smith,et al. Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial , 2021, Blood.
[2] C. Turtle,et al. Autologous Transplant versus Chimeric Antigen Receptor T-cell Therapy for Relapsed DLBCL in Partial Remission. , 2021, Blood.
[3] M. Mohty,et al. Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies , 2021, Blood Cancer Journal.
[4] K. Meehan,et al. Should Thiotepa-Based Regimens Be the New Transplant Conditioning Strategy for Primary Central Nervous System Lymphoma? , 2021, JAMA oncology.
[5] Matthew J. Frigault,et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma , 2021, Leukemia.
[6] K. Ahn,et al. Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era? , 2020, Blood.
[7] Ash A. Alizadeh,et al. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. , 2020, Blood advances.
[8] S. Fujiwara,et al. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study , 2020, International Journal of Hematology.
[9] M. Kersten,et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study , 2020, Haematologica.
[10] M. Shipp,et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: Two-year follow-up of KEYNOTE-087. , 2019, Blood.
[11] R. Suzuki,et al. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] C. Martínez,et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] N. Russell,et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma , 2018, British journal of haematology.
[14] S. Montoto,et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR , 2018, Cancer.
[15] P. Hari,et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. , 2017, Blood.
[16] R. Houot,et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. , 2017, Blood.
[17] R. Houot,et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. , 2017, Blood.
[18] A. Nademanee,et al. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] Alan M. Miller,et al. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] A. Zelenetz,et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. , 2015, Blood.
[21] E. Kimby,et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma , 2014, Leukemia.
[22] D. Niederwieser,et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] E. Hoster,et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.